drugset

Drugs / EPP-AF

Follow last change Oct 2023 re-read 2 minutes ago

EPP-AF

also known as Propolis Standardized

Developed for: vulvovaginal candidiasis · COVID-19
Investigated by: University of Sao Paulo

Trials 1 · a red edge is where a trial was stopped

today NCT03024502 · Ph 1/2

201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT03024502	Jan 2018 → Jan 2020	vulvovaginal candidiasis	University of Sao Paulo	Unknown	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT04800224 Comparator	Apr → Jul 2021	COVID-19	D'Or Institute for Research and Education	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	EPP-AF	“The Use of Brazilian Green Propolis Extract (EPP-AF®) in Patients Affected by COVID-19” NCT04800224 ↗ 1 NCT03024502 ↗
Known as	Propolis Standardized	“the objective of developing a mucoadhesive gel containing Propolis Standardized (EPP-AF®) for the treatment of vaginal candidiasis” NCT03024502 ↗
Route	Oral	“Patients were allocated to receive an oral dose of 900 mg/day of EPP-AF® or placebo for 10 days.” PMID 37891178 ↗ Oct 2023